Cell and gene therapies are at a pivot point. These breakthrough therapies show big promise — but the business models to support these new advances are racing to catch up with the science. Can we keep up the pace in the current climate? Find out at Cell & Gene Day 2024, a free virtual event, WATCH ON DEMAND HERE.
Precision will be at this year’s Meeting on the Med, April 9-11, 2023, in Rome, Italy. Connect with our team of experts as they lead meaningful presentations and discussions throughout this event providing insights into the clinical development, manufacturing, and commercialization for cell and gene therapies.
Connect with our Advanced Therapy experts
You can register for Meeting on the Med below:
Precision will be at this year’s Gene Therapy for Rare Disorders on March 26-29, 2024, in Boston, MA. Connect with our team of experts as they lead meaningful presentations and discussions throughout this event providing insights into the clinical development, manufacturing, and commercialization for gene therapies.
Speaking Engagements
Detailed descriptions for each speaking engagement are included below.
Connect with our Advanced Therapy experts
—
Plenary Speaking Position: What to Look Forward to for Gene Therapy in 2024
Precision | March 27, 2024, 8:30 – 9AM ET
Speakers:
Panel Discussion: Manufacturing Track: Capacity versus Capability – Moving Towards Innovative Manufacturing Processes
Precision | March 28, 2024, 11:15AM – 12:15PM ET
Precision will be at this year’s Advanced Therapies Week, January 16 – 19, in Miami, FL. Connect with our team of experts as they lead meaningful presentations and discussions throughout this event providing insights into the clinical development, manufacturing, and commercialization for advanced therapies.
Speaking Engagements
Detailed descriptions for each speaking engagement are included below.
Connect with our Advanced Therapy experts
You can register for Advanced Therapies Week below:
This article was originally published on This Month in Transformative Medicine on October 17, 2023
The current standard of cancer care has saved many lives, but these methods often come with incredibly difficult side effects. Advancements in technology have brought new options to cancer care that hope to provide meaningful outcomes while minimizing the impact to the patient’s quality of life.
In this white paper Anshul Mangal, President of Project Farma (PF) & Precision ADVANCE, and Sumit Verma, Co-founder and Partner at Orchestra Life Sciences, discuss the power and potential of radioligand therapies and its impact on the treatment of a number of cancers.
Sponsored by Precision ADVANCE, this Endpoints webinar convened industry leaders to discuss the current state of the industry, and the future of advanced therapies including innovations in research and development, going from treating rare diseases to prevalent conditions, continued investment, and next-generation technologies. The panelists also discussed manufacturing and talent bottlenecks, and innovative reimbursement payment models. This discussion was moderated by Anshul Mangal: President (Precision ADVANCE & Project Farma), and included insights from Dan Kirby: Chief Commercial Officer (Orca Bio), Deborah Phippard: CSO (Precision for Medicine), Devyn Smith: CEO (Arbor Bio), Helen Sabzevari: President & CEO (Precigen) and Chad Salisbury: SVP (Project Farma).
Precision will be at HLTH 2023, October 8 – 11, in Las Vegas, NV. Connect with our team of experts as they lead meaningful discussions and attend networking events focused on innovation and transformation for better patient health and treatment outcomes.
Connect with one our experts!
In the rapidly evolving landscape of advanced therapies, allogeneic cell therapies have emerged as a promising avenue for addressing various disorders, including hematological malignancies, neurological conditions, and autoimmune or inflammatory diseases. With a number of clinical trials underway to evaluate their efficacy, allogeneic cell therapies hold significant potential in reshaping the way we approach treating numerous diseases.
In this white paper, Anshul Mangal, President of Project Farma & Precision ADVANCE and John Khoury, Executive Vice President of Project Farma (PF), discuss the growth of the allogeneic cell therapy sector and its impact on patient access.
Precision will be at this year’s Association for Value-Based Cancer Care 2023 Educational Summit & Program, October 18 – 20, NYC, NY. This exclusive invitational forum provides invaluable time with more than 200 diverse experts representing every stakeholder of the cancer care ecosystem.
Don’t miss an opportunity to celebrate groundbreaking science and network with industry leaders!
Speaking Engagements
Detailed descriptions for each speaking engagement are included below.
You can register for the Association for Value-Based Cancer Care 2023 Educational Summit & Program below:
Sponsored by Project Farma, a Precision for Medicine Company, this panel will feature insights from industry leaders on the current state of the market for mRNA-based medicines, techniques to optimize manufacturing and technical operations, and strategies for CQV, quality, automation & engineering for mRNA facilities.
This discussion will be moderated by Anshul Mangal: President (Project Farma & Precision ADVANCE), and include insights from Aaron Allen: Director, Global Quality, External Engagement (Moderna), Andrew Geall: Co-founder and Chief Development Officer (Replicate Bioscience), Jane True: Global VP, mRNA Commercial Strategy Innovation & Pandemic Security Lead (Pfizer), Venkata Indurthi: CSO (Aldevron), and Chad Salisbury: SVP (Project Farma).